Logo

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

Share this

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

Shots:

  • The approval is based on a P-II ZUMA-5 study assessing Yescarta (axicabtagene ciloleucel) in 146 patients aged ≥18rs. with r/r iNHL- prior treated with at least 2L of systemic therapy
  • The P-II ZUMA-5 study showed 91% of patients responded to a single infusion of Yescarta- including ~74% of patients in a continued remission @18mos.; mDoR was not yet reached @median follow-up of 14.5 mos. In the safety analysis- grade 3 or higher CRS and neurologic toxicities occurred in 8% and 21% of patients respectively
  • Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma- follows FDA’s BTD and PR and marks the third approved indication for the therapy

 ­ Ref: Gilead | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions